Emcure Pharmaceuticals has received approval for the acquisition of 4,095,180 equity shares, constituting 20.42% of the total issued and paid-up capital of Zuventus Healthcare (Zuventus), a subsidiary of the company, from all its individual shareholders, thereby making Zuventus a wholly-owned subsidiary of the company.
The Board of Directors of the company at its meeting held on June 21, 2025, has approved the same.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
